Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche FY08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche FY08

Total sales were up 6% in local currencies (-1% in Swiss francs; +10% in U.S. dollars), with the Pharmaceuticals Division representing 79% of group sales and the Diagnostics Division contributing 21%, compensating for the decline in Tamiflu pandemic sales

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche FY08

FY Revenues: $43.3 billion (-1%)

FY Earnings: $10.3 billion (-5%)

Comments: Total sales were up 6% in local currencies (-1% in Swiss francs; +10% in U.S. dollars), with the Pharmaceuticals Division representing 79% of group sales and the Diagnostics Division contributing 21%, compensating for the decline in Tamiflu pandemic sales (down $1.5 billion to $577.7 million) due to reduced pandemic stockpiling orders. Pharmaceutical sales were $34.1 billion (-2% CHF, +8% USD). Genentech revenue accounted for $9.9 billion of Roche’s total, while Chugai revenue accounted for $3.2 billion. Growth was driven by oncology drugs including Avastin, MabThera/Rituxan, Herceptin, Tarceva and Xeloda, with sales up 15% to $18.7 billion. Additional growth drivers were Bonviva/Boniva with sales up 35% to $1.0 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters